busi upgrad
report limit sole use client wolf research pleas refer disclosur section locat end report analyst
certif disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc
distributor stabl busi upgrad outperform
upgrad outperform peer perform increas year-end target price
upsid believ core distribut busi prove resili move stay-at-hom recess
normal recessionari environ disrupt mck busi prove mostli transitori
manag cheapest stock group adjust opioid liabil cost all-tim low
rel valuat despit improv result fundament head crisi believ show best
ep growth group next sever year abil deploy capit less imped opioid settlement
fundament januari feel like sever year ago start year clear sens distribut
fundament least stabl improv inflect real debat whether stock head
meaning re-rat potenti even opioid settlement reach interestingli group seem
revert show-m stori despit gener consensu pharma distribut busi hold better
busi recess
valuat trade opioid adjust ep earn uncertain
use firm estim trade impli rel price-to-earnings multipl well-
histor averag appear all-tim low year-end target price use target price-to-earnings multipl
rel price-to-earnings compar averag
capit deploy share count guidanc y/i appear reflect share repurchas alreadi
complet remain impact transact leav capit deploy upsid
opioid develop sinc outbreak intensifi encourag
sign head ny trial state made comment suggest could satisfi lower end
settlement ask key mdl attorney suggest would satisfactori paid front someth think
merit given current borrow cost addit state local budget go signific strain
plaintiff could priorit near-term payment els continu assum settlement base case
settlement would clear posit group expect would drive multipl expans
risk risk includ polit drug price reform head presidenti elect financi health custom opioid
litig settlement process becom intract impact sever anticip
compani data factset wolf research llc
rel price return
rel price return xlv
compani data factset wolf research llc
rel price return
rel price return xlv
compani data factset wolf research llc
note total return reflect annual dividend yield compar year-end price target
compani data factset wolf research llc
year-end price rel price dividend rel dividend total rel performunderperformoutperform analyst analyst analyst summari estim chang
fiscal estim chang fiscal estim chang
fiscal estim chang fiscal estim chang
compani data factset wolf research llc
estim vs consensu estim vs consensu
estim vs consensu estim vs consensu
compani data factset wolf research llc
distributor reason avoid
reason
 pharma distribut fundament stabil improv
 pharma distribut busi like prove resili recessionari environ
compel valuat absolut rel even adjust opioid
capit return stori post settlement potenti except
biosimilar interest call option
reason avoid
financi health custom could result pressur econom
polit drug price reform risk presidenti elect year
disclosur remain fairli weak hard push back black-box critiqu
compani data factset wolf research llc
look distributor valuat vs entir univers
organ screen pull compani use financi metric look trial valuat metric
data categor decil rank lowest price-to-earnings gross margin highest unlev yield
receiv score
show distributor metric as-report basi also pro-forma interest expens would requir fund
up-front distributor settlement on-going opioid litig
distributor score well yield unlev yield gross margin as-report adjust basi
distributor rank slightli higher price-to-earnings score decil opioid liabil adjust
compar come within decil opioid adjust
howev note mani compani lower trail price-to-earnings ratio come industri much
dramat impact energi airlin cruis line etc
includ gross margin think provid insight distributor see lower decrement
margin compani
trail metric as-report opioid adjust
note opioid adjust metric reduc earn cash flow base amount interest expens requir fund -front opioid settlement also
add back opioid legal expens exclud adjust earn
compani data factset wolf research llc
recal takeaway posit take
januari feel like sever year ago start year clear sens distribut fundament
least stabl improv inflect real debat whether stock head meaning re-
rate potenti even opioid settlement reach
price return
takeaway confer
bullish outlook specialti market relat busi
biosimilar final come great signific investor
brand inflat msd consist guidanc
expect gener deflat compar
re-open pharmedium memphi facil year
outlook commerci busi anim health remain strong
ig rate flexibl priorit share repurchas
wr view messag gener consist prior commentari real
surpris us pretti much right fairway
takeaway confer
bullish outlook specialti market relat busi
brand inflat msd consist guidanc
gener improv market dynam pharma distribut overal stabil
cardin at-hom strong continu streamlin rest medic busi
focus organiz effort reduc cost
ig rate grow dividend priorit share repurchas
importantli believ busi
wr view compani seem make progress result continu trail
peer bit disconnect tone result
takeaway confer
rais fiscal ep guidanc driven momentum pharma
bullish outlook specialti market relat busi
brand inflat msd consist guidanc
gener environ stabl buy sell side grown gross profit
va renew expect materi impact fy result
skeptic benefit price reimport propos
exit possibl end fiscal year
wr view improv outlook pleasant surpris veteran affair outcom seem
better fear rel out-performance seem justifi
price return
price return
compani data factset wolf research llc
 xlvv xlvv xlvv distribut ebit growth fairli strong recent quarter
compani make concert effort track estim unusu item influenc report growth rate
includ cost item invest estim contract renew impact chang opioid litig expens
overal core result distribut fairli strong past quarter
 specialti y/i growth
note show calendar quarter compani
compani data factset wolf research llc
show spend growth categori past year
brand tradit remain histor level due combin lower brand inflat specialti
growth remain robust gener market basic stabl quarter signific declin
compani data factset wolf research llc
shown gener drug market growth decomposit gener deflat moder significantli
gener drug market growth decomposit april march
signific contribut new gener
less contribut new gener
note retail mail channel non-retail primarili provider-bas exclud
iqvia wolf research llc
genericsyear volumematur pricetot gener market gener deflat price chang matur gener drug
measur y/i price declin matur gener drug march februari ytd
oral drug gener market see matur drug price y/i march februari
 ytd
note retail mail channel non-retail primarili provider-bas exclud
iqvia wolf research llc
gener profit indictor independ pharmaci
think compar deflat trend chain store independ may provid read-through independ
margin trend given chain store distributor similar gener drug acquisit cost purchas
gener togeth consortium
chain store measur y/i price declin matur gener march februari
ytd
independ price declin march februari ytd
calendar chain store acquisit cost declin faster independ acquisit cost impli
distributor margin independ expand
calendar independ acquisit cost chain store acquisit cost declin
note analysi would identifi margin headwind come independ
note chain store independ channel
iqvia wolf research llc
rx volum neg impact stay-at-hom order
prescript volum neg impact stay-at-hom order result lower physician util
lead fewer new prescript replac prescript run cours
prescript remain well pre-covid level stabil show earli sign recoveri earli may
iqvia compani data factset wolf research llc
 week chang rx volum neg impact stay-at-hom order
iqvia compani data factset wolf research llc
 week week week week chang new brand rx nbrx trend show weekli improv
note new brand rx nbrx new therapi start rx switch/add-on rx analysi includ retail mail channel
iqvia factset wolf research llc
pronounc declin specialti provid volum primarili non-oncolog market
oncolog evidenc us oncolog practic despit declin routin offic visit consult follow-up
see rel sign stabil oncolog volum patient remain treatment regimen ceo brian tyler
iqvia compani data factset wolf research llc
specialti oncolog interact recov baselin level
iqvia compani data factset wolf research llc
state-level data suggest reopen drive recoveri util
state-level data georgia suggest util start recov state reopen
georgia allow certain busi reopen stay-at-hom end
louisiana stay-at-hom order extend less clear util particularli lab elect
show strong rebound
new rx growth week vs
lab volum growth week vs
elect procedur growth week vs
wolf research llc
nearli state path reopen partial reopen soon
wolf research llc
decreas pharma ebit guidanc lsd
impli impact annual basi
decreas pharma ebit guidanc msd
declin lsd declin
note major guidanc revis
due cah nuclear pharmaci busi tie
procedur rather prescript high
issu pharma revenu guidanc growth
compar
pharma ebit declin growth
declin impli
issu european pharma revenu guidanc
declin vs growth
growth declin impli
compani data factset wolf research llc
decreas distribut ebit guidanc lsd
impli impact annual basi
maintain medic guidanc ldd growth
declin growth declin
impli
declin declin declin impli
ebit ex chang hc declin
growth declin impli
compani data factset wolf research llc
covid impact medium-term long-term trend watch
financi custom base
one key risk monitor financi health distributor custom
distributor gener earn higher margin smaller custom independ pharmaci busi
shift concentr buyer chain pharmaci result independ pharmaci closur would
headwind distributor earn
may key chain pharmaci contract renew recent seem possibl custom could tri
extract improv term distributor
 bit follow-up prior question economi normal recess hope could spend
littl time talk think financi health custom could see busi
impact come month year exampl headlin news today even larg well-fund
busi seek relief landlord guess anyth custom ask stage insight
convers custom would help thank
thank question realli good question weve work custom sinc pandem realli
start particularli custom shut door temporari basi record small increment
reserv medic busi call realli mechan adjust weve work close
tri understand custom would reopen demand busi point custom
either abl go get loan access public fund avail work close us weve abl
help realli understand situat weve realli seen degrad credit qualiti point
continu work close relationship point think custom resili well close
work keep credit resili possibl cfo britt vitalon earn call
yeah base way weve describ expect volum come back gradual cours year
base see call built assumpt major insolv event
assumpt play correct believ base convers see continu true risk well
monitor close cours year ceo brian tyler earn call
wsj compani data factset wolf research llc
chain store increas market share financi crisi trend predat financi crisi
impact varieti non-econom factor cvss acquisit caremark rx close may
prescript market share channel
compani data factset wolf research llc
look back prescript trend financi crisi surpris see well total prescript
held total prescript never declin quarterli basi
obvious recess never includ stay-at-hom order current expect move
somewhat normal recess next month
unemploy current well-abov financi crisi level protect risk
insur loss given structur chang brought afford act
y/i prescript growth calendar quarter
iqvia compani data factset wolf research llc
increas mail order penetr could pressur profit sustain
outbreak intensifi patient began stay home notabl increas mail order
penetr howev trend start unwind move april may
volum shift mail order neg distributor econom mail typic lowest margin busi
overal mail penetr remain quit low unlik telehealth degre structur barrier
place limit adopt impli less risk us catalyz signific shift
compani data factset wolf research llc
rise telemedicin becom headwind rx growth
telemedicin util increas dramat result stay-at-hom order
seem unlik telemedicin util remain current level healthcar system begin re-open
current crisi help remov mani barrier adopt
interestingli iqvia data suggest significantli fewer prescript written telehealth visit although
differ explain patient health statu acut presum like offic visit
continu monitor trend probabl earli treat signific risk
compani data factset wolf research llc
trump administr made meaning progress drug price reform date
juli trump administr withdrew propos elimin exist rebat safe harbor protect within medicar
part medicaid rulemak price demonstr project appear hold
drug price reform import tenant presumpt democrat nomine biden healthcar platform get
vote senat would remain quit challeng even democrat sweep upcom elect
success develop wide-scal manufactur vaccin could insul pharmaceut
industri disrupt either trump biden administr
iqvia recent polici propos impact probabl
iqvia global use medicin outlook wolf research llc
last materi updat opioid settlement talk came mid-march
updat
new york time provid updat opioid
disagr among state continu articl
includ notabl detail potenti settlement structur
accord distributor would pay
settlement state confirm local govt board
type structur refer cramdown could
prove problemat term get local govt on-board
state urg distributor increas offer
would bring total
near lower end previous
discuss sought holdout state
paul hanley lead mdl attorney said propos
would accept paid one two three
year gener littl long
appear consist previou
settlement framework legal fee ad
compani data factset wolf research llc
trial settlement catalyst date trial unclear
trial combin case brough new york attorney gener
nassau counti ny suffolk counti ny
case part opioid multidistrict litig mdl
schedul start delay
trial yet appear reschedul
track bellweth case consist huntington wv cabel
counti case
case part opioid multidistrict litig mdl
schedul begin unclear whether delay
serv
demonstr track mdl case ohio trial start
date import catalyst settlement negoti
also appear true ny case
latest updat prior slide come immedi prior
schedul start trial
fight sever
mdl plaintiff prepar potenti run
sever case bellweth case pharmaci
distributor manufactur separ
compani data factset wolf research llc
merit up-front opioid settlement payment
up-front payment lever distributor pull lieu increas total owe think someth
serious consid
current rate stretch payment year reduc opioid liabil npv vs pay front
small spread result assumpt like tobacco payment stream adjust inflat
credit agenc discuss plan includ opioid settlement npv leverag calcul post settlement
dont think approach would chang alter conclus materi unless signific differ
discount methodolog compani would like insight reach decis
shown up-front lower npv settlement paid year npv
yield-to-matur long-dat bond after-tax ytm opioid scenario discount rate
npv opioid settlement scenario assum year payment stream
data factset
npvheadlin npvheadlin npv leverag scenario up-front opioid settlement
compani data factset wolf research llc
net settlement net settlement net settlement net leverag leverag scenario up-front opioid settlement
compani data factset wolf research llc
net settlement net settlement net settlement net leverag leverag scenario up-front opioid settlement
note cash flow histor heavili weight quarter
compani data factset wolf research llc
state budget like highli challeng econom disrupt could lead state
interest settl opioid litig rel near-term vs draw negoti trial
nation associ state budget offic fall fiscal survey taxfound org wolf research llc
valuat deep-div comparison healthcar subsector
show current multipl drug distributor rang opioid liabil scenario
also show current multipl healthcar subsector
ntm price-to-earnings multipl distributor vs healthcar subsector
compani data factset wolf research llc
valuat deep-div compani compani comparison
show current multipl drug distributor individu rang opioid liabil scenario
ntm price-to-earnings multipl individu distributor vs
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
abc price-to-earnings multipl opioid scenario see like
histor rel price-to-earnings multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
cah price-to-earnings multipl opioid scenario see like
histor rel price-to-earnings multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
mck price-to-earnings multipl opioid scenario see like
histor rel price-to-earnings multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div group rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
group price-to-earnings multipl opioid scenario see like
group histor rel price-to-earnings multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
price-to-earnings valuat absolut rel
ntm price-to-earnings multipl rel
compani data factset wolf research llc
valuat deep-div comparison healthcar subsector
show current multipl drug distributor rang opioid liabil scenario
also show current multipl healthcar subsector
ntm ev ebitda multipl distributor vs healthcar subsector
compani data factset wolf research llc
valuat deep-div compani compani comparison
show current multipl drug distributor individu rang opioid liabil scenario
calcul distributor current trade fairli narrow band
ntm ev ebitda multipl individu distributor vs
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
abc ev/ebitda multipl opioid scenario see like
histor rel ev ebitda multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
cah ev/ebitda multipl opioid scenario see like
histor rel ev ebitda multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
mck ev/ebitda multipl opioid scenario see like
histor rel ev ebitda multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
valuat deep-div group rel histori
show rel multipl past year vs current rel multipl impli rang opioid liabil
assumpt shade recent year note period signific pressur earn gener deflat
creep risk off-bal liabil on-going opioid litig
group ev/ebitda multipl opioid scenario see like
group histor rel ev ebitda multipl vs rel multipl impli opioid liabil scenario
compani data factset wolf research llc
note npv refer size global assum
ev ebitda valuat absolut rel
ntm ev/ebitda multipl rel
compani data factset wolf research llc
compani data factset wolf research llc
estim estim chang comparison vs consensu
compani data factset wolf research llc
vs vs vs estim estim chang comparison vs consensu
compani data factset wolf research llc
vs vs vs estim estim chang comparison vs consensu
compani data factset wolf research llc
